share_log

National Health Investors Analyst Ratings

Benzinga ·  Nov 28, 2023 12:14
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/28/2023 1.1% Stifel → $55 Reiterates Hold → Hold
11/27/2023 1.1% Wells Fargo $54 → $55 Maintains Equal-Weight
10/03/2023 -0.74% Wedbush → $54 Initiates Coverage On → Neutral
09/28/2023 Berenberg Initiates Coverage On → Hold
09/20/2023 -4.41% Jefferies → $52 Initiates Coverage On → Hold
05/11/2023 -0.74% Wells Fargo $52 → $54 Maintains Equal-Weight
03/29/2023 -8.09% Credit Suisse $55 → $50 Maintains Neutral
12/09/2022 6.62% Credit Suisse $47 → $58 Upgrades Underperform → Neutral
09/26/2022 12.13% Truist Securities $64 → $61 Maintains Hold
06/21/2022 13.97% BMO Capital → $62 Downgrades Outperform → Market Perform
04/19/2022 12.13% BMO Capital $63 → $61 Maintains Outperform
02/01/2022 -6.25% Credit Suisse → $51 Initiates Coverage On → Underperform
01/07/2022 25% BMO Capital → $68 Upgrades Market Perform → Outperform
07/23/2021 32.35% Wells Fargo $74 → $72 Maintains Equal-Weight
06/18/2021 30.51% BMO Capital → $71 Upgrades Underperform → Market Perform
03/30/2021 41.54% Capital One → $77 Downgrades Overweight → Equal-Weight
01/13/2021 1.1% Mizuho → $55 Downgrades Neutral → Underperform
01/08/2021 BMO Capital Downgrades Market Perform → Underperform
12/14/2020 Keybanc Upgrades Underweight → Sector Weight
09/02/2020 15.81% Stifel → $63 Reinstates → Hold
06/24/2020 17.65% SunTrust Robinson Humphrey $61 → $64 Maintains Hold
06/17/2020 21.32% Wells Fargo $54 → $66 Maintains Equal-Weight
06/08/2020 JMP Securities Reinstates → Market Perform
05/22/2020 1.1% Mizuho $60 → $55 Downgrades Buy → Neutral
05/14/2020 -26.47% Keybanc $43 → $40 Maintains Underweight
04/23/2020 12.13% SunTrust Robinson Humphrey $77 → $61 Maintains Hold
04/21/2020 -20.96% Keybanc $65 → $43 Maintains Underweight
03/26/2020 -6.25% Wells Fargo $82 → $51 Maintains Equal-Weight
02/05/2020 Berenberg Initiates Coverage On → Buy
01/07/2020 50.74% BMO Capital → $82 Upgrades Underperform → Market Perform
12/20/2019 74.63% Mizuho → $95 Assumes → Buy
02/20/2019 BMO Capital Downgrades Market Perform → Underperform

What is the target price for National Health Investors (NHI)?

The latest price target for National Health Investors (NYSE: NHI) was reported by Stifel on November 28, 2023. The analyst firm set a price target for $55.00 expecting NHI to rise to within 12 months (a possible 1.10% upside). 8 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for National Health Investors (NHI)?

The latest analyst rating for National Health Investors (NYSE: NHI) was provided by Stifel, and National Health Investors reiterated their hold rating.

When is the next analyst rating going to be posted or updated for National Health Investors (NHI)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of National Health Investors, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for National Health Investors was filed on November 28, 2023 so you should expect the next rating to be made available sometime around November 28, 2024.

Is the Analyst Rating National Health Investors (NHI) correct?

While ratings are subjective and will change, the latest National Health Investors (NHI) rating was a reiterated with a price target of $0.00 to $55.00. The current price National Health Investors (NHI) is trading at is $54.40, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment